Clinical Trials
26 trialsNCT06997068 2026-05-11
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
NCT00076310 2026-04-15
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01927744 2025-11-26
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00405405 2025-05-06
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00448240 2025-03-18
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Henry Ford Health System
Phase 2/3 Terminated
NCT00720304 2024-08-22
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00079053 2023-08-04
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Canadian Cancer Trials Group
Phase 1 Completed
NCT02748707 2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2 Unknown
NCT00750555 2019-02-26
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Geisinger Clinic
Phase 2 Terminated
NCT00573989 2019-01-03
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Wake Forest University Health Sciences
Phase 1/2 Terminated
NCT01116336 2018-12-05
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
Emory University
Phase 1 Completed
NCT00030576 2018-10-10
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT00601913 2018-07-05
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Completed
NCT00400374 2018-03-15
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
Emory University
Phase 1 Completed
NCT00304278 2017-07-27
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Southern Illinois University
Phase 2 Completed
NCT00970502 2017-04-10
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00281866 2016-10-12
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00779389 2016-01-13
Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
University of Pittsburgh
Phase 1 Completed
NCT00570232 2015-05-21
UAB0718
University of Alabama at Birmingham
Phase 2 Completed
NCT00144976 2015-03-27
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma
Institut Claudius Regaud
Phase NA Completed
NCT00738751 2015-02-04
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00392704 2013-02-22
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00140556 2013-01-18
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT00113347 2012-02-27
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Completed